Deepbridge’s Life Science Fund sees subscriptions rise 40% over the last 6 months, compared with the same time period in the previous year.
Dr Savvas Neophytou, Partner and Head of Life Sciences at Deepbridge Capital, “The past twelve months has shone a spotlight on the world-leading innovation in the UK life sciences sector like never before, and we have understandably seen significant growth in investor interest as a result.”
The Deepbridge Life Sciences SEIS enables private investors to access a portfolio of early-stage companies within the UK’s vibrant life sciences sector, whilst benefiting from the generous potential tax reliefs available via the Government’s Seed Enterprise Investment Scheme (SEIS).
Deepbridge deployed capital into six companies in the Life Science SEIS fund this tax year; Carocell Bio, Circada, FlutterLab, GenoMe Diagnostics, Glucose Republic and NanOptima.
Deepbridge welcomed its first Northern Ireland based investee company, GenoMe Diagnostics. Neophytou, added, “From northeast Scotland to southwest England, now across all four home nations, we are supporting the very best life sciences innovations, entrepreneurs and scientists.”
Applications for this tax year (2020/21) are now closed, but if you would like to register to apply to next year, sign up here.
